[go: up one dir, main page]

NO981984D0 - Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere - Google Patents

Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere

Info

Publication number
NO981984D0
NO981984D0 NO981984A NO981984A NO981984D0 NO 981984 D0 NO981984 D0 NO 981984D0 NO 981984 A NO981984 A NO 981984A NO 981984 A NO981984 A NO 981984A NO 981984 D0 NO981984 D0 NO 981984D0
Authority
NO
Norway
Prior art keywords
peridone
aqueous suspension
fatty acid
acid esters
hydroxy
Prior art date
Application number
NO981984A
Other languages
English (en)
Other versions
NO315931B1 (no
NO981984L (no
Inventor
Marc Karel Jozef Francois
Roger Carolus August Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981984(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO981984D0 publication Critical patent/NO981984D0/no
Publication of NO981984L publication Critical patent/NO981984L/no
Publication of NO315931B1 publication Critical patent/NO315931B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO19981984A 1996-05-20 1998-04-30 Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere NO315931B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (3)

Publication Number Publication Date
NO981984D0 true NO981984D0 (no) 1998-04-30
NO981984L NO981984L (no) 1998-11-19
NO315931B1 NO315931B1 (no) 2003-11-17

Family

ID=8224016

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19981984A NO315931B1 (no) 1996-05-20 1998-04-30 Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere
NO2011015C NO2011015I2 (no) 1996-05-20 2011-08-29 Paliperidon palmitatester

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2011015C NO2011015I2 (no) 1996-05-20 2011-08-29 Paliperidon palmitatester

Country Status (38)

Country Link
US (1) US6077843A (no)
EP (1) EP0904081B1 (no)
JP (1) JP3274687B2 (no)
KR (1) KR100358373B1 (no)
CN (1) CN1093762C (no)
AR (1) AR007194A1 (no)
AT (1) ATE208619T1 (no)
AU (1) AU715572B2 (no)
BG (1) BG62684B1 (no)
BR (1) BR9706824B8 (no)
CA (1) CA2236691C (no)
CY (2) CY2270B1 (no)
CZ (1) CZ291284B6 (no)
DE (2) DE69708284T2 (no)
DK (1) DK0904081T3 (no)
EA (1) EA000536B1 (no)
EE (1) EE03594B1 (no)
ES (1) ES2167745T3 (no)
FR (1) FR11C0035I2 (no)
HK (1) HK1017852A1 (no)
HR (1) HRP970276B1 (no)
HU (2) HU224025B1 (no)
ID (1) ID16927A (no)
IL (1) IL124551A (no)
LU (1) LU91842I2 (no)
MX (1) MX9804816A (no)
MY (1) MY126302A (no)
NO (2) NO315931B1 (no)
NZ (1) NZ330369A (no)
PL (1) PL188309B1 (no)
PT (1) PT904081E (no)
SI (1) SI0904081T1 (no)
SK (1) SK284013B6 (no)
TR (1) TR199800923T2 (no)
TW (1) TW487572B (no)
UA (1) UA61898C2 (no)
WO (1) WO1997044039A1 (no)
ZA (1) ZA974331B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999043300A1 (en) * 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
CN1208090C (zh) 1999-03-31 2005-06-29 詹森药业有限公司 在控制释放制剂中的预胶凝淀粉
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR20080028513A (ko) * 2000-08-14 2008-03-31 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MXPA05001191A (es) * 2002-07-29 2005-09-12 Johnson & Johnson Metodos y formas de dosificacion para la administracion controlada de paliperidona.
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
WO2005070332A1 (en) * 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
JP5315336B2 (ja) * 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
US9439906B2 (en) 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
PT2341905T (pt) 2008-09-04 2020-07-27 Amylin Pharmaceuticals Inc Formulações de libertação sustentada utilizando transportadores não aquosos
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
KR101936968B1 (ko) 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012164582A1 (en) 2011-05-31 2012-12-06 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HRP20240022T1 (hr) 2015-04-07 2024-03-29 Janssen Pharmaceutica Nv Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
LT4025188T (lt) 2020-11-30 2024-03-12 Janssen Pharmaceutica Nv Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HRP20240086T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
HU219487B (hu) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
WO1996039397A1 (en) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
UA61898C2 (en) 2003-12-15
CY2011011I2 (el) 2016-12-14
HUS1100013I1 (hu) 2017-03-28
HRP970276A2 (en) 1998-04-30
HK1017852A1 (en) 1999-12-03
NO2011015I1 (no) 2011-09-19
HRP970276B1 (en) 2002-04-30
MY126302A (en) 2006-09-29
BG62684B1 (bg) 2000-05-31
SI0904081T1 (en) 2002-04-30
NO2011015I2 (no) 2013-03-11
DE69708284D1 (de) 2001-12-20
JP2000513718A (ja) 2000-10-17
CY2011011I1 (el) 2016-12-14
CA2236691A1 (en) 1997-11-27
BG102443A (en) 1999-06-30
ID16927A (id) 1997-11-20
NZ330369A (en) 2000-04-28
IL124551A0 (en) 1998-12-06
CN1206347A (zh) 1999-01-27
HUP9901319A3 (en) 1999-11-29
CZ291284B6 (cs) 2003-01-15
JP3274687B2 (ja) 2002-04-15
ZA974331B (en) 1998-11-19
PL188309B1 (pl) 2005-01-31
US6077843A (en) 2000-06-20
ATE208619T1 (de) 2001-11-15
PT904081E (pt) 2002-04-29
EE03594B1 (et) 2002-02-15
HU224025B1 (hu) 2005-05-30
FR11C0035I2 (fr) 2013-08-16
EA199800531A1 (ru) 1998-12-24
CA2236691C (en) 2007-01-02
KR19990067603A (ko) 1999-08-25
DK0904081T3 (da) 2002-02-25
AU2955997A (en) 1997-12-09
FR11C0035I1 (no) 2011-07-10
SK284013B6 (sk) 2004-08-03
EA000536B1 (ru) 1999-10-28
NO315931B1 (no) 2003-11-17
HUP9901319A2 (hu) 1999-08-30
CZ140198A3 (cs) 1999-04-14
CY2270B1 (en) 2003-07-04
KR100358373B1 (ko) 2003-02-11
DE122011100027I1 (de) 2011-11-17
BR9706824B8 (pt) 2015-02-18
TR199800923T2 (xx) 1999-09-21
AU715572B2 (en) 2000-02-03
CN1093762C (zh) 2002-11-06
ES2167745T3 (es) 2002-05-16
MX9804816A (es) 1998-10-31
WO1997044039A1 (en) 1997-11-27
TW487572B (en) 2002-05-21
IL124551A (en) 2001-08-26
DE69708284T2 (de) 2002-07-25
BR9706824A (pt) 1999-03-23
PL327995A1 (en) 1999-01-04
EP0904081B1 (en) 2001-11-14
AR007194A1 (es) 1999-10-13
EE9800136A (et) 1998-10-15
NO981984L (no) 1998-11-19
EP0904081A1 (en) 1999-03-31
SK62098A3 (en) 2000-04-10
LU91842I2 (fr) 2011-09-20

Similar Documents

Publication Publication Date Title
NO981984D0 (no) Vandig suspensjon av 9-hydroksyrisperidon-fettsyre estere
NO20002278L (no) Vandige suspensjoner av mikropartikkelformede 9- hydroksyrisperidonfettsyreestere
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
PT0900782E (pt) Ester do acido 2-cianacrilico
NO994595L (no) Salt av naftyridin-karboksylsyrederivat
DE59913680D1 (de) Fettsäurepartialester von Polyolen
NO993796D0 (no) Fremgangsmåte for omforestring av <alfa>-ketokarboksylsyreestre
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
DE69515479D1 (de) Fettsäureester von verätherten polyalkoholen
FI951329A0 (fi) Prostaglandiinin F estereitä
DE59812612D1 (de) Enzymatische Herstellung von regioselektiven Fettsäureestern der Ascorbinsäure
DE69809692D1 (de) Herstellung von Carbonsäureestern
ATE221519T1 (de) Ester von 3-hydroxy-piperidinmethanol-derivaten

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: XEPLION; NAT. REG. NO/DATE: EU/1/11/672/001/NO 20110304; FIRST REG. NO/DATE: EU/1/11/672/001-006 20110304

Spc suppl protection certif: 2011015

Filing date: 20110829

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: XEPLION; NAT. REG. NO/DATE: EU/1/11/672/001/NO 20110304; FIRST REG. NO/DATE: EU/1/11/672/001-006 20110304

Spc suppl protection certif: 2011015

Filing date: 20110829

Extension date: 20220512

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2011015